Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. A Phase 2 Study to Evaluate Safety and Anti-Tumor Activity of Avelumab in Combination With Talazoparib in Patients With BRCA or ATM Mutant Tumors.
Category & Conditions: Cancer
Medicine: Bavencio (avelumab)
Talzenna (talazoparib)
ClinicalTrials.gov Identifier (NCT): NCT03565991
Protocol ID: B9991032
PrintDownloadOpen Plain Language Summary Result: Click here